Top

05-08-2017 | Nausea and vomiting | Review | Article

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics

Journal: Cancer Chemotherapy and Pharmacology

Author: Melissa E. Badowski

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV.

Methods

A PubMed search of the English-language literature available through 4 January 2017 was conducted to identify relevant articles for inclusion in the review.

Results

Oral cannabinoids have been shown to have similar or improved efficacy compared with conventional antiemetics for the resolution of nausea and/or vomiting in patients with cancer. However, oral THC has high PK variability, with variability in oral dronabinol peak plasma concentrations (C _max) estimated between 150 and 200%. A new oral dronabinol solution has decreased intraindividual variability (area under the curve) vs oral dronabinol capsules. Further, oral THC has a slower time to C _max compared with THC administered intravenously (IV) or by smoking, and a lower systemic availability than IV or smoked THC. The PD profile (e.g., “high”) of oral THC differs from that of IV or smoked THC in healthy individuals. Oral cannabinoids are associated with greater incidence of adverse effects compared with conventional antiemetic therapy or placebo (e.g., dizziness, hypotension, and dysphoria or depression).

Conclusions

A new formulation of oral cannabinoids (i.e., dronabinol oral solution) minimized the PK/PD variability currently observed with capsule formulations.

Escobar Y, Cajaraville G, Virizuela JA, Alvarez R, Munoz A, Olariaga O, Tames MJ, Muros B, Lecumberri MJ, Feliu J, Martinez P, Adansa JC, Martinez MJ, Lopez R, Blasco A, Gascon P, Calvo V, Luna P, Montalar J, Del BP, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23(9):2833–2840CrossRefPubMedCentral

Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–851CrossRefPubMed

Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367CrossRef

Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMed

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity–state of the art. Support Care Cancer 19(Suppl 1):S43–S47CrossRefPubMed

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG (2012) Antiemesis. J Natl Compr Cancer Netw 10(4):456–485CrossRef

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198CrossRefPubMedCentral

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRefPubMed

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Antiemesis. (2016). Accessed 5 May 2016

10.

Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20–28

11.

Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRefPubMed

12.

Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10(1):68–74CrossRefPubMed

13.

Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362(10):865–869CrossRefPubMedPubMedCentral

14.

Gomez DR, Liao KP, Giordano S, Nguyen H, Smith BD, Elting LS (2013) Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer 119(7):1428–1436CrossRefPubMed

15.

Chan A, Low XH, Yap KY (2012) Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 18(5):385–394PubMed

16.

Van Laar ES, Desai JM, Jatoi A (2015) Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer 23(1):151–157CrossRefPubMedPubMedCentral

17.

Wilkie G, Sakr B, Rizack T (2016) Medical marijuana use in oncology: a review. JAMA Oncol 2(5):670–675CrossRef

18.

Pacher P, Kunos G (2013) Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J 280(9):1918–1943CrossRefPubMedPubMedCentral

19.

Marinol^® (dronabinol) capsules [package insert] (2017) AbbVie Inc., North Chicago

20.

Cesamet^® (nabilone) capsules for oral administration [package insert] (2013) Meda Pharmaceuticals, Somerset

21.

SYNDROS^TM (dronabinol) oral solution, CX [package insert] (2016) Insys Therapeutics, Inc., Chandler

22.

Sallan SE, Zinberg NE, Frei EI (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293(16):795–797CrossRefPubMed

23.

Machado Rocha F, Stéfano S, De Cássia HR, Rosa Oliveira LM, Da Silveira D (2008) Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17(5):431–443CrossRef

24.

Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303):16–21CrossRefPubMedPubMedCentral

25.

Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464

26.

Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Cancer Netw 10(4):487–492CrossRef

27.

Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg SA (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746–1751CrossRef

28.

Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM (2012) Novel ∆⁹-tetrahydrocannabinol formulation Namisol^® has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 74(1):42–53CrossRefPubMed

29.

Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F (2005) Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 29(8):782–789CrossRefPubMed

30.

Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C (2014) Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol 24(9):1475–1482CrossRefPubMed

31.

Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105(1–2):79–88CrossRefPubMed

32.

Wall ME, Perez-Reyes M (1981) The metabolism of ∆⁹-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21(8–9 Suppl):178S–189SCrossRefPubMed

33.

Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR (2013) Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of ∆⁹-THC in cannabis users. J Clin Pharmacol 53(7):680–690CrossRefPubMedPubMedCentral

34.

McGilveray IJ (2005) Pharmacokinetics of cannabinoids. Pain Res Manag 10(Suppl A):15A–22ACrossRefPubMed

35.

Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42(4):327–360CrossRefPubMed

36.

Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16(5):276–282CrossRefPubMed

37.

Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28(3):409–416CrossRef

38.

Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA (2015) Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem 61(6):850–869CrossRefPubMed

39.

Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S (1981) Do plasma concentrations of ∆⁹-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 21(8–9 Suppl):171S–177SCrossRefPubMed

40.

Cesari M, Landi F, Torre S, Onder G, Lattanzio F, Bernabei R (2002) Prevalence and risk factors for falls in an older community-dwelling population. J Gerontol A Biol Sci Med Sci 57(11):M722–M726CrossRefPubMed

41.

Parikh N, Kramer WG, Khurana V, Cognata Smith C, Vetticaden S (2016) Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol 8:155–162PubMedPubMedCentral

42.

Abrams DI, Guzman M (2015) Cannabis in cancer care. Clin Pharmacol Ther 97(6):575–586CrossRefPubMed

43.

Whiting PF, Wolff RF, Deshpande S, Di NM, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473CrossRefPubMed

44.

Ghosh TS, Van Dyke M, Maffey A, Whitley E, Erpelding D, Wolk L (2015) Medical marijuana’s public health lessons—implications for retail marijuana in Colorado. N Engl J Med 372(11):991–993CrossRefPubMed

45.

Moeller KE, Woods B (2015) Pharmacy students’ knowledge and attitudes regarding medical marijuana. Am J Pharm Educ 79(6):85CrossRefPubMedPubMedCentral

46.

Birdsall SM, Birdsall TC, Tims LA (2016) The use of medical marijuana in cancer. Curr Oncol Rep 18(7):40CrossRefPubMed

47.

MacCoun RJ, Mello MM (2015) Half-baked–the retail promotion of marijuana edibles. N Engl J Med 372(11):989–991CrossRefPubMed

48.

Nelson B (2015) Medical marijuana: hints of headway? Despite a conflicted regulatory landscape, support for medical marijuana is growing amid increasing evidence of potential benefits. Cancer Cytopathol 123(2):67–68CrossRefPubMed

49.

Monte AA, Zane RD, Heard KJ (2015) The implications of marijuana legalization in Colorado. JAMA 313(3):241–242CrossRefPubMedCentral

50.

Poster DS, Penta JS, Bruno S, Macdonald JS (1981) ∆⁹-tetrahydrocannabinol in clinical oncology. JAMA 245(20):2047–2051CrossRef

51.

Zhang MW, Ho RC (2015) The cannabis dilemma: a review of its associated risks and clinical efficacy. J Addict 2015:707596CrossRefPubMedPubMedCentral

52.

Joy J, Watson S, Benson JJ (eds) (1999) Marijuana and medicine: assessing the science base. National Academy Press, Washington, D.C

53.

Slatkin NE (2007) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5(5 Suppl 3):1–9PubMed